CK Life Sciences Int'l. (Holdings) Inc
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; m… Read more
CK Life Sciences Int'l. (Holdings) Inc (LSI) - Net Assets
Latest net assets as of June 2025: €3.65 Billion EUR
Based on the latest financial reports, CK Life Sciences Int'l. (Holdings) Inc (LSI) has net assets worth €3.65 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.29 Billion) and total liabilities (€7.63 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.65 Billion |
| % of Total Assets | 32.37% |
| Annual Growth Rate | -3.51% |
| 5-Year Change | -25.58% |
| 10-Year Change | -17.56% |
| Growth Volatility | 8.25 |
CK Life Sciences Int'l. (Holdings) Inc - Net Assets Trend (2013–2024)
This chart illustrates how CK Life Sciences Int'l. (Holdings) Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CK Life Sciences Int'l. (Holdings) Inc (2013–2024)
The table below shows the annual net assets of CK Life Sciences Int'l. (Holdings) Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.51 Billion | -16.18% |
| 2023-12-31 | €4.19 Billion | +0.81% |
| 2022-12-31 | €4.16 Billion | -7.67% |
| 2021-12-31 | €4.50 Billion | -4.61% |
| 2020-12-31 | €4.72 Billion | +13.02% |
| 2019-12-31 | €4.17 Billion | -5.55% |
| 2018-12-31 | €4.42 Billion | -7.08% |
| 2017-12-31 | €4.76 Billion | +6.84% |
| 2016-12-31 | €4.45 Billion | +4.53% |
| 2015-12-31 | €4.26 Billion | -12.63% |
| 2014-12-31 | €4.87 Billion | -6.26% |
| 2013-12-31 | €5.20 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to CK Life Sciences Int'l. (Holdings) Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 321.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.21 Billion | 62.94% |
| Other Components | €1.30 Billion | 37.06% |
| Total Equity | €3.51 Billion | 100.00% |
CK Life Sciences Int'l. (Holdings) Inc Competitors by Market Cap
The table below lists competitors of CK Life Sciences Int'l. (Holdings) Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Wongtee International Enterprise Co Ltd
SHE:000056
|
$213.53 Million |
|
Lintes Technology Co Ltd
TW:6715
|
$213.62 Million |
|
Wuxi Xinhongye Wire & Cable Co. Ltd. A
SHE:301310
|
$213.72 Million |
|
Nanjing Chixia Development Co Ltd
SHG:600533
|
$213.87 Million |
|
2Seventy Bio Inc
NASDAQ:TSVT
|
$213.50 Million |
|
Beijing Changjiu Logistics Ltd
SHG:603569
|
$213.49 Million |
|
Movida Participações S.A
SA:MOVI3
|
$213.48 Million |
|
Nanjing Panda Electronics Company Limited
F:NNJ
|
$213.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CK Life Sciences Int'l. (Holdings) Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,189,253,000 to 3,511,548,000, a change of -677,705,000 (-16.2%).
- Net loss of 126,554,000 reduced equity.
- Other factors decreased equity by 551,151,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-126.55 Million | -3.6% |
| Other Changes | €-551.15 Million | -15.7% |
| Total Change | €- | -16.18% |
Book Value vs Market Value Analysis
This analysis compares CK Life Sciences Int'l. (Holdings) Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.24x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.48 | €0.09 | x |
| 2018-12-31 | €0.44 | €0.09 | x |
| 2019-12-31 | €0.43 | €0.09 | x |
| 2020-12-31 | €0.49 | €0.09 | x |
| 2021-12-31 | €0.47 | €0.09 | x |
| 2022-12-31 | €0.43 | €0.09 | x |
| 2023-12-31 | €0.44 | €0.09 | x |
| 2024-12-31 | €0.37 | €0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CK Life Sciences Int'l. (Holdings) Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.29%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 3.07x
- Recent ROE (-3.60%) is below the historical average (3.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 4.60% | 4.61% | 0.49x | 2.05x | €-268.69 Million |
| 2014 | 5.65% | 5.32% | 0.48x | 2.21x | €-202.71 Million |
| 2015 | 5.32% | 4.45% | 0.52x | 2.31x | €-192.65 Million |
| 2016 | 5.85% | 5.18% | 0.51x | 2.21x | €-179.09 Million |
| 2017 | 5.60% | 5.51% | 0.44x | 2.29x | €-203.30 Million |
| 2018 | 6.17% | 5.03% | 0.50x | 2.45x | €-163.39 Million |
| 2019 | 4.35% | 3.66% | 0.46x | 2.56x | €-236.01 Million |
| 2020 | 2.65% | 2.53% | 0.41x | 2.54x | €-346.89 Million |
| 2021 | 3.61% | 3.01% | 0.46x | 2.60x | €-287.56 Million |
| 2022 | 3.17% | 2.50% | 0.47x | 2.71x | €-283.86 Million |
| 2023 | 0.41% | 0.32% | 0.47x | 2.68x | €-401.68 Million |
| 2024 | -3.60% | -2.29% | 0.51x | 3.07x | €-477.71 Million |
Industry Comparison
This section compares CK Life Sciences Int'l. (Holdings) Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CK Life Sciences Int'l. (Holdings) Inc (LSI) | €3.65 Billion | 4.60% | 2.09x | $213.50 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |